阿托伐他汀早期干预对2型糖尿病合并高血压患者血脂及炎症因子水平的影响

Effect of Early Atorvastatin Intervention on Blood Lipid and Inflammatory Factors of Patients with Type 2 Diabetes and Hypertension

目的:探讨早期阿托伐他汀钙片干预对2型糖尿病合并高血压患者血脂水平和炎症指标的影响。方法:选择2014年5月-2015年5月我院收治的2型糖尿病合并高血压患者130例,根据治疗方法不同,将患者分为研究组和对照组,每组各65例。对照组采取常规降压及降糖药物治疗,研究组在此基础上应用阿托伐他汀钙片。观察两组患者治疗前后血脂水平、高敏C-反应蛋白(hs-CRP)、白介素-6(IL-6)及白介素-18(IL-18)的变化情况。结果:治疗后,两组患者胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)水平均较治疗前降低,且研究组显著低于对照组,差异具有统计学意义(P<0.05);两组患者治疗前后的甘油三脂(TG)及高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05);治疗后,两组患者hs-CRP、IL-6及IL-18水平均较治疗前降低,且研究组显著低于对照组,差异具有统计学意义(P<0.05);两组不良反应的发生率比较,差异无统计学意义(P>0.05)。结论:阿托伐他汀钙片可以有效改善2型糖尿病合并高血压患者的血脂水症,降低血清炎症因子的表达,值得临床推广应用。

Objective： To investigate the changes of blood lipid levels and inflammatory markers of patients with type 2 diabetes and hypertension by atorvastatin intervention. Methods： 130 patients with type 2 diabetes and hypertension who were treated in our hospital from May 2014 to May 2015 were selected and according to the different treatment methods, the patients were divided into the study group and the control group with 65 cases in each group. The patients in the control group were treated with the routine anti-hypertensive and hypoglycemic methods, while the patients in the study group were treated with atorvastatin besides the conventional methods. Then the changes of blood lipid, C-reactive protein, IL-6 and IL-18 of patients in the two groups were observed and compared before and after the treatment. Results： After treatment, the levels of TC and LDL-C in the two groups were lower than before, and the study group was lower than that of the control group with statistically significant differences （P〈0.05）; There was no statistically significant difference about the TG and the HDL-C in the two groups （P〉0.05）. After treatment, the levels of hs-CRP, IL-6 and IL-18 in the two groups were lower than before, and the study group was loWer than that of the control group with statistically significant differences （P〈0.05）; There was no statistically significant difference about the adverse reactions in the two groups （P〉0.05）. Conclusion： Atorvastatin can effectively improve the blood lipid, reduce the expressions of inflammatory factors for the patients with type 2 diabetes and hypertension, which is worthy of clinical application.